Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
None Gilead Sciences, Inc. is set to present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026 in Denver, Colorado. The data will examine durability of response, patient-relevant symptoms, and opportunities to better understand long-term disease management across these rare and serious liver diseases. Gilead’s scientific program includes 21 accepted abstracts, including late-breaking Phase 3 research from the Livdelzi (seladelpar) 10 mg development program and new long-time evidence for Hepcludex (bulevirtide-gmod) 2 mg and 8.5 mg in chronic HDV. Additional data on safety and efficacy of seladelpar up to five years and late-break data on fatigue will also be presented. The company continues to drive innovation and progress scientific advancements to inform treatment decisions and enhance understanding of rare liver diseases and its commitment to improving outcomes.
प्रकाशित : 6 घंटे पहले द्वारा में Health Science
Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting ®... [20104 symbols]
विषय: Data
